S. Y. Rha Et Al. , "The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma," ANNALS OF ONCOLOGY , 2023
Rha, S. Y. Et Al. 2023. The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. ANNALS OF ONCOLOGY .
Rha, S. Y., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J., ... Yanez Weber, P. E.(2023). The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. ANNALS OF ONCOLOGY .
Rha, S. Et Al. "The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma," ANNALS OF ONCOLOGY , 2023
Rha, S. Y. Et Al. "The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma." ANNALS OF ONCOLOGY , 2023
Rha, S. Y. Et Al. (2023) . "The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma." ANNALS OF ONCOLOGY .
@article{article, author={S. Y. Rha Et Al. }, title={The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma}, journal={ANNALS OF ONCOLOGY}, year=2023}